戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 itative rather than qualitative estimates of residual risk.
2 es as a novel marker of or target to address residual risk.
3 ntially to the disease burden and perpetuate residual risk.
4 to identify unique HFrEF subgroups with high residual risk.
5 redictor of incident events and biomarker of residual risk.
6 om VLDL and chylomicrons, contribute to this residual risk.
7 rapy, Lp(a) was a significant determinant of residual risk.
8  novel therapies are required to reduce this residual risk.
9 C, apolipoprotein B, or ratios in predicting residual risk.
10 stions about its value for stratification of residual risk.
11 few treatments are documented to reduce this residual risk.
12          Lipoprotein(a) levels may influence residual risk.
13 e clinical biomarker to identify patients at residual risk.
14 allow better estimation of carrier rates and residual risks.
15 essential to sustain these gains and address residual risks.
16 nt to 40% or higher (HFimpEF) may still face residual risks.
17 g hold incremental predictive information on residual risk after acute coronary syndrome beyond that
18 35 mg/dL may reduce lipoprotein-attributable residual risk after acute coronary syndrome.
19  goal of this study was to determine whether residual risk after high-dose statin therapy for primary
20 r particle number (HDL-P) as determinants of residual risk after potent statin therapy.
21 tic techniques enables the estimation of the residual risk after the consumption of a product that un
22 s in medium- and high-risk patients, and the residual risk after these cut points were 0.2% for low-r
23 ng strategies with a second test to identify residual risk among those deemed low risk by the first t
24 innovative clinical trial designs to address residual risk and identify novel therapeutic targets.
25                                  The overall residual risk and the risk associated with these measure
26 mbined cholesterol and inflammatory risk, no residual risk, and isolated residual cholesterol risk.
27                             Understanding of residual risk, anxiety levels, and overall satisfaction
28                        Factors mediating the residual risk are incompletely characterized.
29 erol with statins, there remains significant residual risk as evidenced by incident and recurrent car
30 d abnormal lipids, ideal treatment goals and residual risk, as well as statin potency.
31 dictor of future cardiovascular events as is residual risk assessed by low-density lipoprotein choles
32                                          The residual risk at guideline-recommended targets was estim
33  screening panels, they recommend to compute residual risk based on ethnicity.
34 admission, there should be consideration for residual risk based on the LDL/HDL ratio, following stro
35 to study therapeutic approaches that address residual risk beyond LDL-C reduction to promote plaque s
36                                          The residual risk conferred by low HDL-C in patients with a
37  lipoproteins (TRLs) represents an important residual risk factor for cardiovascular and chronic kidn
38                                              Residual risk factors are associated with the likelihood
39 ency, PIK3CA mutations do not seem to affect residual risk following treatment with endocrine therapy
40 ological characteristics that differentiated residual risk for cardiovascular death or heart failure
41  LDL-C as the primary target of therapy, yet residual risk for cardiovascular disease (CVD) among sta
42 pective on some of these salient issues: the residual risk for disease progression after sustained vi
43 educed ejection fraction (HFrEF) have a high residual risk for heart failure hospitalizations and car
44 te coronary syndromes (NSTE-ACS) are at high residual risk for long-term cardiovascular (CV) mortalit
45 patients on MRA therapy may remain at a high residual risk for poor outcomes even on MRA therapy.
46 tor-positive breast cancer have considerable residual risk for recurrence after completing 5 years of
47 lity that HDL modification could address the residual risk has brought renewed focus on an old HDL-ra
48 The pursuit of novel therapies to target the residual risk has focused on raising the levels of high-
49                       Risk factors for this "residual risk" have not been studied comprehensively.
50  with proper risk mitigation strategies; the residual risk, however, should be weighed carefully agai
51 it is associated with a progressively higher residual risk, ie, higher treatment failures.
52 festyle counseling more effective; assessing residual risk in a treated patient; diagnosing and treat
53 rogress of the diagnostic toolbox to measure residual risk in elderly individuals.
54                            Evaluation of the residual risk in patient with chronic coronary syndrome
55 ide-rich lipoproteins (TRLs) are a source of residual risk in patients with atherosclerotic cardiovas
56        Lipoprotein(a) [Lp(a)] is a source of residual risk in patients with atherosclerotic cardiovas
57                              Determinants of residual risk in statin-treated secondary prevention pat
58 res help to identify patients at the highest residual risk in the present era.
59 is unknown whether Lp(a) is a determinant of residual risk in the setting of low low-density lipoprot
60                              Estimated viral residual risks increased slightly after the attacks (HIV
61  States, there is a need to better integrate residual risk into cardiovascular disease (CVD) risk str
62  progression of diabetic kidney disease, the residual risk is high.
63                                              Residual risk is related to residual albuminuria.
64  candidate genes that may contribute to this residual risk is the endothelial nitric oxide synthase (
65 recognition of the role of inflammation as a residual risk marker of adverse outcomes for coronary ar
66  Lp(a) levels, possibly contributing to the "residual risk" noted in outcomes trials and at the bedsi
67 nt for 10 years) would lead to expected mean residual risk of 14.6% (A; ARR 2.6%) or 13.9% (B; ARR 3.
68 ol in identifying statin-treated patients at residual risk of all-cause mortality and myocardial infa
69 but not LDL cholesterol, are associated with residual risk of all-cause mortality and myocardial infa
70 evels are lower than guideline thresholds, a residual risk of atherosclerosis remains.
71 nchmark TTR to achieve further mitigation of residual risk of bleeding and enhance haemocompatibility
72 in Lp(a) concentrations were associated with residual risk of cardiovascular disease (adjusted hazard
73      Moreover, even with adequate control, a residual risk of cardiovascular events and associated or
74 iovascular disease and MetS have substantial residual risk of cardiovascular events despite statin th
75 ognised in nephrology, could help to explain residual risk of cardiovascular events in the general po
76 e anti-inflammatory medication to target the residual risk of cardiovascular events in the secondary
77 oduction of these therapeutics, an important residual risk of CKD progression and cardiovascular deat
78 eutic strategies, there remains an extensive residual risk of clinical events, particularly in high-r
79                                          The residual risk of COVID-19 deaths in ethnic minority grou
80 ant associations of a similar magnitude with residual risk of CVD were found for on-treatment LDL-C,
81 d atherogenic particles were associated with residual risk of CVD/all-cause death.
82      Despite treatment, there is substantial residual risk of disease progression with existing thera
83                           In The Gambia, the residual risk of HBV MTCT exceeds the elimination absolu
84                                     However, residual risk of heart failure persists in many individu
85                                          The residual risk of HIV transfusion transmission through co
86 eening for HIV, HCV, and HBV has reduced the residual risk of infectious-window-period donations, suc
87  patients with cardiovascular disease have a residual risk of ischaemic events despite receiving anti
88 s; change in population-level incidence; and residual risk of Kaposi's sarcoma.
89 n and may account, at least in part, for the residual risk of lung cancer among former smokers.
90 tion and lowering cholesterol, a significant residual risk of major atherosclerotic complication rema
91              This study aimed to analyze the residual risk of MI, together with relevant associated f
92 ovascular treatment goals is associated with residual risk of mortality and cardiovascular outcomes i
93 n the association between Lp(a) and the high residual risk of myocardial infarction, providing suppor
94                         We observed that the residual risk of recurrence was higher in breast cancer
95       However, there are limited data on the residual risk of recurrent stroke in patients with AF.
96 er women treated with warfarin have a higher residual risk of stroke in comparison with men.
97 s clopidogrel/aspirin can further reduce the residual risk of stroke recurrence in patients with posi
98 thogen-reduction technologies to address the residual risk of TAS as well as the potential risk of th
99  HCV infections annually and has reduced the residual risk of transfusion-transmitted HIV-1 and HCV t
100 nd kidney events when used individually, the residual risks of these events remain high across major
101                             Treatment of the residual risk, other than blood pressure and LDL-cholest
102  the cardiovascular-metabolic component, and residual risk persists despite healthy lifestyles and tr
103                                              Residual risk persists despite statin therapy and additi
104 individuals with established CHD, to improve residual risk prediction and identify novel drug targets
105               As a result, carrier rates and residual risks provided for patient decision-making are
106 ion of classic CVD risk factors, significant residual risks remain.
107 C declined over the 3 years, but substantial residual risk remained in the third year, leading to 90.
108 explained by health behaviors, although some residual risk remained unexplained.
109 sures can mitigate mortality rates; however, residual risk remains even at speeds of 10 knots or less
110                                 Nonetheless, residual risk remains high, and statin intolerance is fr
111 ite statin treatment, cardiovascular disease residual risk remains high.
112 scular events by about 25-35%, a substantial residual risk remains, leading to a search for additiona
113 et levels of LDL-C, and thus, LDL-associated residual risk remains.
114 eurotransmitter noradrenaline, a substantial residual risk remains.
115 tes; despite strict control, however, a high residual risk remains.
116 tion we observed between RCB and a patient's residual risk suggests that prospective evaluation of RC
117 DL particle number may be a better marker of residual risk than chemically measured HDL-C or apoA-I.
118 o estimated the potential risk reduction and residual risk that can be achieved if patients reach gui
119 ts a promising candidate to address the high residual risk that persists in ACS patients receiving gu
120 A1/2 pathogenic variant (PV) carriers have a residual risk to develop peritoneal carcinomatosis (PC).

 
Page Top